2024
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance
Conway K, Edmiston S, Vondras A, Reiner A, Corcoran D, Shen R, Parrish E, Hao H, Lin L, Kenney J, Ilelaboye G, Kostrzewa C, Kuan P, Busam K, Lezcano C, Lee T, Hernando E, Googe P, Ollila D, Moschos S, Gorlov I, Amos C, Ernstoff M, Cust A, Wilmott J, Scolyer R, Mann G, Vergara I, Ko J, Rees J, Yan S, Nagore E, Bosenberg M, Rothberg B, Osman I, Lee J, Saenger Y, Bogner P, Thompson C, Gerstenblith M, Holmen S, Funchain P, Brunsgaard E, Depcik-Smith N, Luo L, Boyce T, Orlow I, Begg C, Berwick M, Thomas N, Berwick M, Luo L, Boyce T, Reynolds A, Wiggins C, Thomas N, Conway K, Edmiston S, Ollila D, Hao H, Parrish E, Googe P, Moschos S, Corcoran D, Vondras A, Tsai Y, Lin L, Shen R, Begg C, Arora A, Seshan V, Reiner A, Kostrzewa C, Busam K, Orlow I, Lezcano C, Kenney J, Sadeghi K, O'Connell K, Ilelaboye G, Parmar H, Leong S, Corrales S, Scolyer R, Cust A, Wilmott J, Mann G, Shang P, Burke H, Ferguson P, Jakrot V, Lee T, Hernando E, Osman I, Hanniford D, Argibay D, Moran U, Heguy A, Ramaswami S, Amos C, Gorlov I, Zhu D, Ernstoff M, Bogner P, Lee J, Rees J, Yan S, Gerstenblith M, Thompson C, Ko J, Funchain P, Ngo P, Bosenberg M, Gould Rothberg B, Panse G, Saenger Y, Fullerton B, Holmen S, Colman H, Brunsgaard E, Wada D, Nagore E, Manrique-Silva E, Requena C, Traves V, Millan-Esteban D, Rainka M. DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO Precision Oncology 2024, 8: e2400375. PMID: 39509669, PMCID: PMC11737429, DOI: 10.1200/po-24-00375.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerCpG island methylator phenotypePrimary melanomaBreslow thicknessMethylation classClinicopathological characteristicsN stageRisk of melanoma-related deathLow methylationStage IIRetrospective case-control studyCutaneous primary melanomaHigher AJCC stagePrimary cutaneous melanomaHigher N stageMelanoma-related deathDNA methylation classDied of melanomaMitotic indexCase-control studyIII patientsClinicopathological factorsCpG island hypermethylationPrognostic significanceAJCC stageImmune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers
Kim J, Hong J, Lee J, Jung M, Choi E, Cho N, Kang G, Kim S. Immune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers. Cancer Immunology, Immunotherapy 2024, 73: 215. PMID: 39235590, PMCID: PMC11377388, DOI: 10.1007/s00262-024-03805-3.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1Tumor-infiltrating lymphocytesMicrosatellite instability-high colorectal cancerCombined positive scoreTumor proportion scoreTumor mutational burdenCD8+ tumor-infiltrating lymphocytesMicrosatellite instability-highTumor-infiltrating immune cellsCpG island methylator phenotypeColorectal cancerCIMP-high tumorsDensity of CD8+ tumor-infiltrating lymphocytesProgrammed death-ligand 1 tumor proportion scoreCIMP-highConsensus molecular subtype 1Cytolytic activity scoreWhole-slide immunohistochemistryDeath-ligand 1Tumor immune microenvironmentMethylator phenotypeMicrosatellite instability-high tumorsTumor DNA methylationDNA methylation phenotypeCpG island methylator phenotype status
2023
Molecular and Sociodemographic Colorectal Cancer Disparities in Latinos Living in Puerto Rico
Perez-Mayoral J, Gonzalez-Pons M, Centeno-Girona H, Montes-Rodríguez I, Soto-Salgado M, Suárez B, Rodríguez N, Colón G, Sevilla J, Jorge D, Llor X, Xicola R, Toro D, Tous-López L, Torres-Torres M, Reyes J, López-Acevedo N, Goel A, Rodríguez-Quilichini S, Cruz-Correa M. Molecular and Sociodemographic Colorectal Cancer Disparities in Latinos Living in Puerto Rico. Genes 2023, 14: 894. PMID: 37107652, PMCID: PMC10138302, DOI: 10.3390/genes14040894.Peer-Reviewed Original ResearchConceptsEarly-onset colorectal cancerColorectal cancerCpG island methylator phenotypeMicrosatellite instabilityExact testColorectal cancer disparitiesSporadic colorectal cancerFisher's exact testMolecular carcinogenic pathwaysClinicopathologic featuresClinicopathological characteristicsCancer deathCancer disparitiesColorectal tumorsCarcinogenic pathwaysHispanic menMutation statusTumorsAdditional studiesMethylator phenotypeHispanic subpopulationsChi-squaredAmerindian admixtureMolecular pathwaysMolecular markers
2021
Effects of Somatic Methylation in Colonic Polyps on Risk of Developing Metachronous Advanced Colorectal Lesions
Murcia O, Martínez-Roca A, Juárez M, Giner-Calabuig M, Alustiza M, Mira C, Mangas-Sanjuan C, Serrano E, Ruiz-Gómez FA, Baile-Maxia S, Medina L, Alenda C, Payá A, Rodriguez-Soler M, Zapater P, Jover R. Effects of Somatic Methylation in Colonic Polyps on Risk of Developing Metachronous Advanced Colorectal Lesions. Cancers 2021, 13: 246. PMID: 33440809, PMCID: PMC7827613, DOI: 10.3390/cancers13020246.Peer-Reviewed Original ResearchCpG island methylator phenotypeAdvanced colorectal lesionsColorectal lesionsColonic polypsRetrospective cohort studyHigh-grade dysplasiaNegative predictive valueBaseline colonoscopyCohort studyConsecutive patientsEndoscopic surveillancePathological characteristicsVillous componentSerrated lesionsPredictive valuePatientsUseful markerSomatic hypermethylationPolyp sizePolypsLesionsMethylator phenotypeSomatic methylationDysplasiaRisk
2018
Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans
Xicola RM, Manojlovic Z, Augustus GJ, Kupfer SS, Emmadi R, Alagiozian-Angelova V, Triche T, Salhia B, Carpten J, Llor X, Ellis NA. Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans. Carcinogenesis 2018, 39: 1331-1341. PMID: 30239619, PMCID: PMC6292413, DOI: 10.1093/carcin/bgy122.Peer-Reviewed Original ResearchMeSH KeywordsAdenomatous Polyposis Coli ProteinBlack or African AmericanCadherinsColorectal NeoplasmsDNA Copy Number VariationsDNA MethylationDNA-Binding ProteinsExome SequencingFemaleGATA6 Transcription FactorHumansMaleMicrosatellite InstabilityMicrosatellite RepeatsMiddle AgedMixed Function OxygenasesProto-Oncogene ProteinsSOX9 Transcription FactorTranscription FactorsWnt Signaling Pathway
2016
Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients
Fu T, Liu Y, Li K, Wan W, Pappou EP, Iacobuzio-Donahue CA, Kerner Z, Baylin SB, Wolfgang CL, Ahuja N. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. Oncotarget 2016, 5: 86480-86489. PMID: 27880934, PMCID: PMC5349928, DOI: 10.18632/oncotarget.13441.Peer-Reviewed Original ResearchConceptsDisease-free survivalStage II colorectal cancer patientsStage II CRC patientsCpG island methylator phenotypeMLH1 methylation statusColorectal cancer patientsOverall survivalLymphovascular invasionCRC patientsCancer patientsMucin productionMethylator phenotypeKaplan-Meier analysisPoor clinical outcomeMethylation statusDuodenal adenocarcinomaClinical outcomesAggressive featuresPoor prognosisPrognostic valuePatient subgroupsTumor locationMultivariate analysisPatientsM groupMethylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma
Fu T, Sharmab A, Xie F, Liu Y, Li K, Wan W, Baylin SB, Wolfgang CL, Ahuja N. Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma. PLOS ONE 2016, 11: e0162929. PMID: 27643594, PMCID: PMC5028050, DOI: 10.1371/journal.pone.0162929.Peer-Reviewed Original ResearchConceptsDisease-free survivalCpG island methylator phenotypeDuodenal adenocarcinomaOverall survivalMethylation of MGMTMGMT methylationMicrosatellite instabilityPoor prognosisKRAS mutationsCox proportional hazards modelMGMT unmethylated groupTumor molecular featuresChemotherapy/radiotherapyIndependent prognostic factorO6-methylguanine-DNA methyltransferase methylation statusWorse overall survivalPossible prognostic valueProportional hazards modelMGMT methylation statusPrognostic factorsClinicopathological characteristicsTumor characteristicsMethylation statusPrognostic valueTumor differentiationEpigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah E, Kerner Z, Nanda N, Ahuja N. Epigenetic therapy in gastrointestinal cancer: the right combination. Therapeutic Advances In Gastroenterology 2016, 9: 560-579. PMID: 27366224, PMCID: PMC4913338, DOI: 10.1177/1756283x16644247.Peer-Reviewed Original ResearchDNA methyltransferaseEpigenetic dysregulationEpigenetic drugsEpigenetic therapyCpG island methylator phenotypeDeoxyribonucleic acid methylationChromatin remodelingHistone modificationsCancer epigenomeEpigenetic reprogrammingWidespread epigenetic dysregulationCancer epigeneticsEpigenetic targetsCancer stem cellsHistone deacetylase inhibitorsMolecular biologyAcid methylationStem cellsDeacetylase inhibitorsDevelopment of drugsEpigeneticsGenetic mutationsMethylator phenotypeChemo resistanceEpigenetic sensitization
2014
Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis
Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, Ahuja N. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Annals Of Oncology 2014, 25: 2314-2327. PMID: 24718889, PMCID: PMC4239805, DOI: 10.1093/annonc/mdu149.Peer-Reviewed Original ResearchConceptsDisease-free survivalCpG island methylator phenotypeColorectal cancer patientsCRC patientsOverall survivalHazard ratioPredictive factorsPrognostic valueCancer patientsPredictive valuePatient disease-free survivalShorter disease-free survivalCancer-specific mortalityAdditional survival benefitMethylator phenotypeShorter overall survivalMicrosatellite instability statusAdjuvant chemotherapyDFS benefitSurvival benefitWorse prognosisCRC prognosisPooled analysisSubgroup analysisNineteen studiesMultiple Sporadic Colorectal Cancers Display a Unique Methylation Phenotype
Gonzalo V, Lozano JJ, Alonso-Espinaco V, Moreira L, Muñoz J, Pellisé M, Castellví-Bel S, Bessa X, Andreu M, Xicola RM, Llor X, Ruiz-Ponte C, Carracedo A, Jover R, Castells A, Balaguer F. Multiple Sporadic Colorectal Cancers Display a Unique Methylation Phenotype. PLOS ONE 2014, 9: e91033. PMID: 24643221, PMCID: PMC3958343, DOI: 10.1371/journal.pone.0091033.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overColorectal NeoplasmsCpG IslandsDNA MethylationEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticGenome-Wide Association StudyGenotypeHumansMaleMiddle AgedNeoplasms, Multiple PrimaryPhenotypeProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras ProteinsConceptsMultiple colorectal cancersColorectal cancerSporadic colorectal cancerMultiple tumorsCpG island methylator phenotypeSolitary tumorTumor multiplicityMismatch repair deficiency statusSynchronous colorectal cancerMethylation phenotypeCIMP-high tumorsDNA methylation profilingDNA hypermethylationBRAF mutationsDeficiency statusSignificant DNA hypermethylationTumorsTumor samplesMethylation profilingMethyLight assayTumor pairsMethylator phenotypeCpG sitesFunctional annotation clusteringPatientsCpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas
Sun L, Guzzetta AA, Fu T, Chen J, Jeschke J, Kwak R, Vatapalli R, Baylin SB, Iacobuzio-Donahue CA, Wolfgang CL, Ahuja N. CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas. Epigenetics 2014, 9: 738-746. PMID: 24518818, PMCID: PMC4063833, DOI: 10.4161/epi.28082.Peer-Reviewed Original ResearchConceptsCpG island methylator phenotypeSporadic duodenal adenomasDuodenal adenomasBRAF mutationsVillous typeMethylator phenotypeCIMP-high statusPeriampullary locationAggressive managementDuodenal adenocarcinomaClinicopathologic featuresColorectal cancerColorectal adenomasKRAS mutationsHigh riskAdenomasMLH1 methylationCIMP statusCancerous lesionsOlder ageP16 methylationTumorsMalignancyInfrequent eventRole of methylation
2013
The CpG Island Methylator Phenotype: What's in a Name?
Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovée JV, French PJ, van den Brandt PA, Schouten LJ, de Meyer T, van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, van Engeland M. The CpG Island Methylator Phenotype: What's in a Name? Cancer Research 2013, 73: 5858-5868. PMID: 23801749, DOI: 10.1158/0008-5472.can-12-4306.Peer-Reviewed Original ResearchConceptsCpG island methylator phenotypeTranslocation methylcytosine dioxygenase 2Tumor typesMethylator phenotypePrimary human astrocytesHuman neoplasiaIsocitrate dehydrogenase 1 (IDH1) mutationCpG island promoter methylationColorectal cancerOllier's diseaseAdrenocortical carcinomaProstate cancerMultiple enchondromasHuman astrocytesClinical practiceRenal cellsIDH2 mutationsCancer typesCancerDioxygenase 2Promoter methylationFunction mutationsMafucci's syndromeNeoplasiaLeukemiaEpigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer
Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M, Ziogas A, Zheng W, Yang H, Wu A, Wozniak E, Ling Woo Y, Winterhoff B, Wik E, Whittemore A, Wentzensen N, Palmieri Weber R, Vitonis A, Vincent D, Vierkant R, Vergote I, Van Den Berg D, Van Altena A, Tworoger S, Thompson P, Tessier D, Terry K, Teo S, Templeman C, Stram D, Southey M, Sieh W, Siddiqui N, Shvetsov Y, Shu X, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen H, Rzepecka I, Runnebaum I, Anne Rossing M, Rodriguez-Rodriguez L, Risch H, Renner S, Poole E, Pike M, Phelan C, Pelttari L, Pejovic T, Paul J, Orlow I, Zawiah Omar S, Olson S, Odunsi K, Nickels S, Nevanlinna H, Ness R, Narod S, Nakanishi T, Moysich K, Monteiro A, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin J, McGuire V, Matsuo K, Mat Adenan N, Massuger L, Lurie G, Lundvall L, Lubiński J, Lissowska J, Levine D, Leminen A, Lee A, Le N, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny G, Krüger Kjaer S, Kiemeney L, Kelemen L, Keeney G, Karlan B, Karevan R, Kalli K, Kajiyama H, Ji B, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall C, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle M, Hall P, Gronwald J, Gore M, Goodman M, Giles G, Gentry-Maharaj A, Garcia-Closas M, Flanagan J, Fasching P, Ekici A, Edwards R, Eccles D, Easton D, Dürst M, du Bois A, Dörk T, Doherty J, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer D, Cook L, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker C, Brueggmann D, Brown R, Brooks-Wilson A, Brinton L, Bogdanova N, Block M, Benjamin E, Beesley J, Beckmann M, Bandera E, Baglietto L, Bacot F, Armasu S, Antonenkova N, Anton-Culver H, Aben K, Liang D, Wu X, Lu K, Hildebrandt M, Schildkraut J, Sellers T, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther S, Pharoah P, Laird P, Goode E, Leigh Pearce C. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications 2013, 4: 1628. PMID: 23535649, PMCID: PMC3848248, DOI: 10.1038/ncomms2629.Peer-Reviewed Original ResearchConceptsDNA methylationAnalyse DNA methylationClear cell epithelial ovarian cancerSingle nucleotide polymorphismsEpigenetic analysisExpression patternsExpression profilesDifferent single nucleotide polymorphismsCpG island methylator phenotypeSusceptibility genesMethylationDistinct mechanismsGenesMethylator phenotypeHNF1BOvarian cancerRisk allelesSerous epithelial ovarian cancerEpithelial ovarian cancerAssociatesEpithelial ovarian cancer riskGenomePromoterPhenotypeAlleles
2011
The CpG island methylator phenotype in colorectal cancer: Progress and problems
Hughes LA, Bakker C, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, Herman JG, Weijenberg MP, van Engeland M. The CpG island methylator phenotype in colorectal cancer: Progress and problems. Biochimica Et Biophysica Acta 2011, 1825: 77-85. PMID: 22056543, DOI: 10.1016/j.bbcan.2011.10.005.Peer-Reviewed Original ResearchConceptsCpG island methylator phenotypeColorectal cancerMethylator phenotypeMolecular pathological epidemiologySporadic colorectal cancerEnvironmental risk factorsPotential clinical importanceMultiple gene panelsOnly original research articlesRisk factorsUnselected seriesInclusion criteriaUnselected casesTrue prevalenceClinical importanceSystematic reviewDisease trendsOriginal research articlesGene panelPrevalenceDistinct subgroupsCancerPrimary causePhenotypeUniversal definitionBreast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis
Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA. Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine 2011, 3: 75ra25. PMID: 21430268, PMCID: PMC3146366, DOI: 10.1126/scitranslmed.3001875.Peer-Reviewed Original ResearchConceptsGenome-wide analysisBreast cancer methylomeBreast cancer epigenomeDistinct epigenomic profilesCancer-specific alterationsMetastatic behaviorHuman malignanciesCancer methylomeCancer epigenomeEpigenomic contributionEpigenomic profilesDNA methylationTranscriptomic changesHypermethylator phenotypeMultiple human malignanciesCpG island methylator phenotypeBreast cancer oncogenesisGenesCancer oncogenesisMethylomeMethylationLociLow metastatic riskMetastatic potentialMethylator phenotype
2010
5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer
Jover R, Nguyen T, Pérez–Carbonell L, Zapater P, Payá A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD, Clofent J, Bujanda L, Reñé JM, Bessa X, Xicola RM, Nicolás–Pérez D, Castells A, Andreu M, Llor X, Boland CR, Goel A. 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer. Gastroenterology 2010, 140: 1174-1181. PMID: 21185836, PMCID: PMC3073650, DOI: 10.1053/j.gastro.2010.12.035.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntimetabolites, AntineoplasticChemotherapy, AdjuvantCohort StudiesColorectal NeoplasmsCpG IslandsDisease-Free SurvivalDNA MethylationFemaleFluorouracilFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedPhenotypePredictive Value of TestsPrognosisProportional Hazards ModelsConceptsCpG island methylator phenotypeCIMP-positive tumorsAdjuvant chemotherapyColorectal cancerCIMP statusColorectal tumorsIndependent predictorsStage IITNM stage IIDisease-free survivalOnly independent predictorPopulation-based cohortResponse of patientsMedian followChemotherapySurvival timePatientsMLH1 promoterMultivariate analysisTumorsAbstractTextMicrosatellite instabilityCIMP-negative tumorsDFSMethylator phenotype745 Colorectal Cancers (CRCs) With the CpG Island Methylator Phenotype (CIMP) Do Not Show Improved Survival With 5-Fluorouracil (5FU)-Based Adjuvant Chemotherapy
Jover R, Nguyen T, Pérez-Carbonell L, Payá A, Alenda C, Rojas E, Castells A, Andreu M, Llor X, Boland C, Goel A. 745 Colorectal Cancers (CRCs) With the CpG Island Methylator Phenotype (CIMP) Do Not Show Improved Survival With 5-Fluorouracil (5FU)-Based Adjuvant Chemotherapy. Gastroenterology 2010, 138: s-102. DOI: 10.1016/s0016-5085(10)60466-0.Peer-Reviewed Original ResearchCpG island methylator phenotypeColorectal cancerAdjuvant chemotherapyImproved survivalMethylator phenotypeChemotherapyCancer
2009
198 CpG-Island Methylator Phenotype (CIMP) and Alterations in RAS-Raf Signaling in Hereditary Non-Polyposis Colorectal Cancers Without Mismatch Repair Deficiency (MSS HNPCC)
Xicola R, Nguyen T, Doyle B, Bandipalliam P, Syngal S, Reyes J, Cordero C, Grzybowski J, Sapoznik V, Grzybowski M, Castells A, Jover R, Andreu M, Boland C, Llor X, Goel A. 198 CpG-Island Methylator Phenotype (CIMP) and Alterations in RAS-Raf Signaling in Hereditary Non-Polyposis Colorectal Cancers Without Mismatch Repair Deficiency (MSS HNPCC). Gastroenterology 2009, 136: a-37. DOI: 10.1016/s0016-5085(09)60169-4.Peer-Reviewed Original Research
2008
CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal Abnormalities in Colorectal Cancer
Cheng YW, Pincas H, Bacolod MD, Schemmann G, Giardina SF, Huang J, Barral S, Idrees K, Khan SA, Zeng Z, Rosenberg S, Notterman DA, Ott J, Paty P, Barany F. CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal Abnormalities in Colorectal Cancer. Clinical Cancer Research 2008, 14: 6005-6013. PMID: 18829479, PMCID: PMC3268558, DOI: 10.1158/1078-0432.ccr-08-0216.Peer-Reviewed Original ResearchConceptsCpG island methylator phenotypeColorectal cancerChromosomal aberrationsLigase detection reactionMicrosatellite instabilityRight-side colonPrimary colorectal cancerColorectal cancer developmentSporadic colorectal cancerSame study cohortCIMP-positive tumorsChromosomal instabilityStudy cohortAberrant promoter methylationPrimary tumorNormal mucosaBRAF mutationsIndependent markerPhenotype associatesDegree of aneuploidyBRAF mutation V600ETumor progressionIndependent molecular mechanismsCancerCancer development
2000
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
Toyota M, Ohe-Toyota M, Ahuja N, Issa J. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 710-715. PMID: 10639144, PMCID: PMC15395, DOI: 10.1073/pnas.97.2.710.Peer-Reviewed Original ResearchMeSH KeywordsAdenomaBase SequenceColorectal NeoplasmsCpG IslandsDNA MethylationDNA Mutational AnalysisDNA, NeoplasmGenes, p16Genes, p53Genes, rasHumansMicrosatellite RepeatsMutationPhenotypePoint MutationPolymorphism, Single-Stranded ConformationalProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSequence DeletionTumor Cells, CulturedConceptsCpG island methylator phenotypeColorectal cancerK-ras mutationsDifferent genetic lesionsActivation of oncogenesTumor suppressor geneMultiple CpG islandsColorectal tumorsMethylator phenotypeCpG islandsDistinct genetic profilesP53 mutationsEpigenetic alterationsMolecular diversitySuppressor geneGenetic lesionsNovel pathwayGroup of tumorsGenetic alterationsK-rasMutationsCancer developmentSimultaneous methylationGenes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply